Durability of glycemic control with insulin lispro mix 75/25 versus insulin glargine for older patients with type 2 diabetes by Lois Jovanovič et al.
ORIGINAL PAPER
Durability of glycemic control with insulin lispro mix 75/25
versus insulin glargine for older patients with type 2 diabetes
Lois Jovanovicˇ • Anne L. Peters •
Honghua H. Jiang • Dana S. Hardin
Received: 26 June 2013 / Accepted: 2 September 2013 / Published online: 3 October 2013
 The Author(s) 2013. This article is published with open access at Springerlink.com
Abstract
Background and Aims Few studies have evaluated long-
term durability of glycemic control in older patients. The
aim of this study was to compare durability of glycemic
control of twice-daily insulin lispro mix 75/25 (LM75/25;
75 % insulin lispro protamine suspension, 25 % insulin
lispro) and once-daily insulin glargine (GL) added to oral
antihyperglycemic medications in older patients
(C65 years of age).
Methods Patients were participants in the maintenance
phase of the DURABLE trial. During the initiation phase,
patients with type 2 diabetes were randomized to LM75/25
or GL. After 6 months, patients with hemoglobin A1c
(HbA1c) B7.0 % advanced to the 24-month maintenance
phase. The primary objective was between-group com-
parison of duration of maintaining the HbA1c goal in older
patients (C65 years of age). A similar analysis was con-
ducted for older patients achieving HbA1c B6.5 % in the
initiation phase.
Results Median time of maintaining HbA1c goal was
longer in LM75/25 versus GL (19.6 versus 15.4 months,
p = 0.007) and more LM75/25 patients maintained goal
versus GL (49.2 versus 30.4 %; p = 0.003). HbA1c
reduction from baseline was greater in LM75/25 versus GL
(-1.56 ± 0.10 versus -1.24 ± 0.11 %; p = 0.003). Post-
meal glucose was significantly lower in LM75/25 versus
GL (158.86 ± 3.42 versus 171.67 ± 4.51 mg/dL;
p = 0.017). No differences were observed in overall and
severe hypoglycemia. LM75/25 patients had higher daily
insulin doses (0.41 ± 0.02 versus 0.32 ± 0.02 units/kg/
day; p \ 0.001) and more weight gain (5.47 ± 0.49 versus
3.10 ± 0.53 kg; p = 0.001). Similar results were generally
obtained in older patients with HbA1c B6.5 %.
Conclusions In our evaluation of older patients from a
larger trial, LM75/25 appeared to provide longer durability
of glycemic control, as well as a greater number of patients
maintaining HbA1c goal versus GL.
Keywords Type 2 diabetes mellitus  Insulin 
Hemoglobin A1c  Aged
Introduction
Type 2 diabetes is one of the most common chronic con-
ditions of older age (C65 years). It is estimated that 20 %
of the older population suffer from type 2 diabetes [1, 2]
and that type 2 diabetes is associated with greater mor-
bidity and mortality in older patients [2]. Management of
type 2 diabetes in older patients can be more challenging
and problematic than in younger patients [3]. Compared
with younger patients, older patients are more likely to
have comorbid conditions that may complicate
management.
This study was presented in abstract and poster form at the European
Association for the Study of Diabetes Annual meeting, Lisbon,
Portugal, 12–16 September 2011.
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There is increased interest in the efficacy and safety of
treatment regimens in older patients, particularly in
understanding safe hemoglobin A1c (HbA1c) targets. To
date, few studies have evaluated long-term durability of
glycemic control in older patients, particularly in the case
of insulin therapy.
The DURABLE trial (assessing the DURAbility of
Basal versus Lispro mix 25 insulin Efficacy) was designed
to study the efficacy, safety, and durability of two starter
insulin regimens (twice-daily insulin lispro mix 75/25
[LM75/25, 75 % insulin lispro protamine suspension, 25 %
insulin lispro] versus once-daily insulin glargine [GL]) in a
large, diverse cohort of patients with type 2 diabetes [4, 5].
At the completion of the 24-week initiation phase, with
continuation of pre-study oral anti-hyperglycemic medi-
cations (OAMs), in the overall study population
(30–80 years of age), efficacy was slightly greater in the
LM75/25 versus GL group, with greater overall prevalence
of hypoglycemia but less nocturnal hypoglycemia [6].
Patients with HbA1c B7.0 % continued into a 24-month
maintenance phase evaluating how long each insulin regi-
men could maintain HbA1c goal. At completion of the
maintenance phase, a modestly longer duration of glycemic
control was achieved in the LM75/25 versus GL group in
the overall group [7]. Wolfenbuttel et al. [8] previously
reported a post-hoc analysis of efficacy and safety from the
initiation phase of the DURABLE trial of a subgroup of
patients C65 years of age and found that LM75/25 dem-
onstrated a lower endpoint HbA1c and a higher percentage
of patients reaching HbA1c target of \7.0 %, but with more
weight gain and higher rates of hypoglycemia compared
with GL.
The objective of the present analysis was to compare the
durability of glycemic control of LM75/25 versus GL in
the subgroup of older patients (C65 years of age) partici-
pating in the maintenance phase of the DURABLE Trial.
Methods
Study design
This study was a post-hoc analysis of a subset of data from
the DURABLE Trial maintenance phase. A detailed
description of the DURABLE study design has been pre-
viously published [4]. Briefly, the DURABLE trial was a
randomized, open-label, parallel, 30-month trial conducted
in 11 countries. The trial enrolled insulin-naı¨ve patients
with type 2 diabetes, aged C30 to \80 yrs, with
HbA1c [7.0 %, on at least 2 oral OAMs: C1,500 mg/day
metformin (MET); at least  maximal daily dose sulfo-
nylurea (SU), or thiazolidinedione (TZD [C30 mg/day
pioglitazone or C4 mg/day rosiglitazone]). In the 24-week
initiation phase [6], patients were randomized 1:1 to LM75/
25 twice daily or GL once daily, both in combination with
pre-study OAM. After the 24-week initiation phase,
patients with HbA1c B7.0 % were followed for up to an
additional 24 months (maintenance phase [7]) to evaluate
how long HbA1c goal could be maintained. The HbA1c goal
was either HbA1c B7.0 % or HbA1c [7.0 %, but
increased \0.4 % from last HbA1c B7.0 %. The LM75/25
starting dose was ten units twice daily, and the GL starting
dose was ten units once daily, both added to pre-study
OAMs. Insulin was adjusted to achieve HbA1c B6.5 %
using regimen-specific insulin-titration algorithms based on
self-monitored plasma glucose review [6]. Patients moni-
tored plasma glucose at least twice daily (before morning
and evening meals). During the 6-month initiation phase,
dose adjustments were reviewed by an external data
monitoring committee; this was not continued during
maintenance because patients had an HbA1c B7.0 %.
Doses were assessed and adjusted B3 months according to
patients’ twice-daily self-monitored plasma glucose values.
The maintenance phase did not include rescue therapy;
therefore, patients were discontinued from the trial if
HbA1c increased to [7.5 %. Hypoglycemia was recorded
any time a patient experienced symptoms of hypoglycemia
or had a self-monitored plasma glucose B70 mg/dL, and
the event was deemed severe if the patient required
assistance.
The present analysis only included data from older
patients (C65 years of age) and primarily compared dura-
tion of maintaining HbA1c goal (HbA1c B7.0 % or
HbA1c [7.0 % with \0.4 % increase from last
HbA1c B7.0 %) for LM75/25 versus GL. Analyses were
also conducted for older patients (C65 years of age)
achieving 24-week HbA1c targets B6.5 %. Secondary
analyses included HbA1c change from baseline (randomi-
zation), plasma glucose profiles at endpoint, weight
change, total daily insulin dose, hypoglycemia rate, and
incidence.
Statistical methods
All analyses were conducted based on the intent-to-treat-
ment population. The primary efficacy measure, the time of
maintaining glycemic control, was compared between
treatment groups with a stratified log-rank test controlling
for country, TZD, and SU use. Categorical variables were
compared with the Fisher exact test. HbA1c change from
baseline to endpoint, endpoint insulin dose, weight change,
and 7-point self-monitored plasma glucose profile were
compared using analysis of covariance (ANCOVA).
Treatment, baseline value (if applicable), and stratification
variables (country, TZD use, and SU use) were included in
the model. Hypoglycemia rates were compared using the
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negative binomial model with factors of treatment, country,
TZD use, and SU use. All analyses were conducted using
SAS 9.2 (SAS Institute Inc., Cary, NC).
Results
Patient disposition and baseline characteristics
Of the 892 patients who entered the maintenance phase,
224 were older (C65 years of age) (LM75/25, n = 133;
GL, n = 91) and made up the study population for this
post-hoc analysis (Fig. 1). A portion of these older patients
achieved the 24-week HbA1C target B6.5 % (LM75/25,
n = 72; GL, n = 39). In all older patients, baseline
demographic characteristics were similar between treat-
ment groups with the exception of use of the SU/TZD
combination which was lower in the LM75/25 group
compared with the GL group (6.1 versus 13.5 %,
p = 0.026) (Table 1). In older patients achieving 24-week
HbA1C targets B6.5 % (LM75/25, n = 72; GL, n = 39) all
baseline demographic characteristics were similar between
the LM75/25 and GL subgroups (Table 1). Baseline gly-
cemic control (HbA1C) was similar between treatment
groups at study entry in patients C65 years of age (LM75/
25 8.5 % versus GL 8.4 %) and in patients C65 years of
age achieving 24-week HbA1C targets B6.5 % (LM75/25
8.3 % versus GL 8.2 %).
Glycemic control
The median time of maintaining HbA1C goal was longer in
LM75/25 versus GL (19.6 months [95 % CI = 14.0, 26.3]
versus 15.4 months [95 % CI = 9.2, 17.3]; p = 0.007,
Fig. 2). More patients in LM75/25 maintained HbA1C goal
versus GL (49.2 versus 30.4 %; p = 0.003). HbA1C
reduction from baseline was greater in LM75/25 versus GL
(-1.56 ± 0.10 versus -1.24 ± 0.11 %; p = 0.003)
(Fig. 3a). Endpoint fasting blood glucose was similar in
LM75/25 versus GL, but post-meal glucose was signifi-
cantly lower in LM75/25 versus GL (158.86 ± 3.42 versus
171.67 ± 4.51 mg/dL; p = 0.017).
Analysis of older patients who achieved HbA1C B6.5 %
also revealed a greater HbA1C reduction from baseline in
LM75/25 versus GL (-1.61 ± 0.14 versus -1.34 ±
0.12 %; p = 0.049) (Fig. 3a). Additionally, post-meal
glucose and the mean of all blood glucose measurements
were significantly lower in LM75/25 versus GL
(150.02 ± 3.52 versus 167.67 ± 7.36 mg/dL; p = 0.016)
and (132.14 ± 2.69 versus 147.83 ± 6.62 mg/dL;
p = 0.013), respectively (Fig. 3b).
Body weight and insulin dose
At endpoint, patients C65 years of age treated with LM75/
25 gained more weight than did patients treated with GL
(5.47 ± 0.49 versus 3.10 ± 0.53 kg; p = 0.001). Similar
weight gains were also observed for the two treatment groups
(LM75/25, n = 71; 5.02 ± 5.69 kg versus GL, n = 38,
2.89 ± 5.44 kg, p = 0.159) in patients C 65 years of age
achieving 24-week HbA1C targets B6.5 %. The total daily
insulin dose at endpoint was higher in patients C65 years of
age treated with LM75/25 versus GL (0.41 ± 0.02 versus
0.32 ± 0.02 units/kg/day; p \ 0.001) but similar for LM75/
25 versus GL in patients C65 years of age achieving
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Fig. 1 Patient disposition in
the maintenance phase of the
DURABLE trial for
patients C65 years. Glargine
insulin glargine, LM75/25
insulin lispro mix 75/25 (75 %
insulin lispro protamine
suspension, 25 % insulin
lispro), OAM oral anti-
hyperglycemic medication
Aging Clin Exp Res (2014) 26:115–121 117
123
Hypoglycemia
At endpoint, the rate (mean ± SD) of overall hypogly-
cemia was 23.21 ± 37.28 versus 19.25 ± 29.34 epi-
sodes/patient/year, p = 0.669. The rate of nocturnal
hypoglycemia was 8.74 ± 21.30 versus 10.99 ± 20.64
episodes/patient/year, p = 0.919) and incidence of severe
hypoglycemia (2.3 versus 3.3 %, p = 0.436). Thus
hypoglycemia was similar for LM75/25 versus GL in
patients C65 years. Interestingly, in patients C65 years
of age achieving 24-week HbA1C targets B6.5 %, the
rate (mean ± SD) of overall hypoglycemia
(22.43 ± 39.91 versus 18.52 ± 24.58 episodes/patient/
year, p = 0.604) and incidence of severe hypoglycemia
(1.4 versus 5.3 %, p = 0.212) were similar for LM75/25
versus GL.
Table 1 Baseline demographic characteristics
Characteristic All HbA1C B6.5 %










Age, years 69.6 ± 4.0 69.4 ± 4.0 69.5 ± 4.0 69.4 ± 4.0
Sex (male/female) 55/36 25/14 79/54 39/33
Race/ethnicity, n (%)
Caucasian 81 (89.0) 34 (87.2) 112 (84.2) 62 (86.1)
African descent 4 (4.4) 2 (5.1) 8 (6.0) 3 (4.2)
Asian 2 (2.2) 0 3 (2.3) 0
Hispanic 4 (4.4) 3 (7.7) 8 (6.0) 6 (8.3)
Other 0 0 2 (1.5) 1 (1.4)
Weight, kg 90.5 ± 18.2 90.5 ± 19.5 88.8 ± 18.4 90.8 ± 17.6
BMI, kg/m2 32.5 ± 5.4 32.3 ± 5.2 31.6 ± 5.2 32.5 ± 5.2
Diabetes duration, years 11.0 ± 6.5 9.7 ± 5.3 12.3 ± 8.0 11.3 ± 7.0
HbA1C (%) 8.4 ± 0.9 8.2 ± 0.7 8.5 ± 1.1 8.3 ± 1.0
FBG
(mg/dL) 183.1 ± 46.3 186.9 ± 47.5 176.6 ± 47.6 172.3 ± 47.7
(mmol/L) 10.2 ± 2.6 10.4 ± 2.6 9.8 ± 2.6 9.6 ± 2.7
Concomitant OAMs, n (%)
Patients with 3 drugs 15 (16.9) 4 (10.3) 32 (24.2) 16 (22.5)
Patients with 2 drugs 74 (83.1) 35 (89.7) 100 (75.8) 55 (77.5)
Sulphonylurea/TZD 12 (13.5) 4 (10.3) 8 (6.1)f 5 (7.0)
Sulphonylurea/metformin 59 (66.3) 30 (76.9) 82 (62.1) 42 (59.2)
TZD/metformin 3 (3.4) 1 (2.6) 10 (7.6) 8 (11.3)
Data are mean ± SD, unless otherwise indicated
BMI body mass index, FPG fasting plasma glucose, HbA1C hemoglobin A1c, Glargine insulin glargine, LM75/25 insulin lispro mix 75/25 (75 %
insulin lispro protamine suspension, 25 % insulin lispro), OAM oral anti-hyperglycemic medication, TZD thiazolidinedione
a Patients with HbA1C B6.5 % at the end of the 24-week initiation phase
b Except for HbA1C (n = 89), FPG (n = 86) and Concomitant OAMs (n = 89)
c Except for HbA1C (n = 37) and FPG (n = 36)
d Except for HbA1C (n = 131), FPG (n = 130) and Concomitant OAMs (n = 132)
e Except for HbA1C (n = 71), FPG (n = 69) and Concomitant OAMs (n = 71)





















p=0.007 between treatment difference
Fig. 2 Time to failure to maintain HbA1C goal. Glargine insulin
glargine, LM75/25 insulin lispro mix 75/25 (75 % insulin lispro
protamine suspension, 25 % insulin lispro)
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Discussion
This post-hoc analysis represents the first comparison of
GL and premix analog insulin for maintaining long-term
insulin therapy in a large population of older patients
(C65 years of age) with type 2 diabetes. LM75/25 therapy
resulted in a longer durability of glycemic control, but with
more weight gain which was associated with modestly
higher daily insulin doses. Hypoglycemia rates and inci-
dence of severe hypoglycemia were similar for LM75/25
versus GL. A greater number of patients treated with
LM75/25 maintained HbA1C goal compared with patients
treated with GL.
Reaching and maintaining glycemic targets reduces the
risk of long-term complications in diabetes. When evalu-
ating therapies, it is important to examine the glycemic
durability (the length of time a patient is able to maintain
glycemic control). In older patients, LM75/25 therapy
resulted in a longer durability of glycemic control, and
more patients maintained HbA1C goal when compared with
GL therapy. The findings of the current analysis are also
comparable to the results of the maintenance phase of the
overall DURABLE trial (ages 30–80 years) in which
LM75/25 therapy resulted in a longer durability of glyce-
mic control and was associated with more weight gain and
modestly higher daily insulin doses [7]. Similarly, a greater
number of LM75/25-treated patients maintained HbA1C
goal compared with patients treated with GL, and no dif-
ferences were observed in hypoglycemia.
Clinical studies have shown that postprandial glucose is
an important contributor to overall glycemic control, par-
ticularly as HbA1C values approach lower target values [9].
In addition, targeting postprandial glucose may reduce the
risk for many diabetes-related complications, but this is
still a subject of intense debate [10]. Premixed insulin
analogs address both preprandial and postprandial blood
glucose targets to more closely mimic physiological insulin
secretion [11]. In the present study, LM75/25 demonstrated
better postprandial glycemic control compared with GL in
all older patients.
Fear of hypoglycemia remains one of the key barriers to
initiating and optimizing insulin therapy [12, 13]. Suc-
cessful insulin therapy involves a delicate balance between
achieving adequate glycemic control while preventing
hypoglycemia. Considering the greater risk for developing
hypoglycemia (and severe hypoglycemia) in older patients
[3], and the greater morbidity associated with hypoglyce-
mia in this population [14], an important finding in this
study was similar rates of overall hypoglycemia, nocturnal
hypoglycemia, and the incidence of severe hypoglycemia
between LM75/25 compared with GL in older patients.
In the subgroup of older patients achieving the more
stringent HbA1C target of B6.5 %, LM75/25 also demon-
strated better postprandial glycemic control compared with
GL and in addition, overall plasma glucose at endpoint was
lower in LM75/25 versus GL in older patients with
HbA1C B6.5 %. Similarly, the rates of hypoglycemia were
similar between the treatment groups in this subgroup of
older patients that achieved HbA1C B6.5 %, although the
numbers in this subgroup are relatively small.
These findings contrast with the earlier analyses of older
patients in the DURABLE trial initiation phase, where rates
of overall hypoglycemia and severe hypoglycemia were
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Fig. 3 a HbA1C change from
baseline to endpoint and
b Plasma glucose at endpoint.
HbA1C glycosylated hemoglobin
A1C, FPG fasting plasma
glucose, Glargine insulin
glargine, LM75/25 insulin lispro
mix 75/25 (75 % insulin lispro
protamine suspension, 25 %
insulin lispro). Data are
mean ± SEM. *Patients with
HbA1C B6.5 % at the end of the
24-week initiation phase
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with GL [8]. One reason for this difference may be that
patients had already achieved glycemic goals in the initi-
ation phase and were, therefore, more stable in the main-
tenance phase with respect to plasma glucose and insulin
dose. Guidelines from the American Diabetes Association
and the American Geriatric Society suggest that less
stringent HbA1C targets might be more appropriate for
some older patients [15, 16], and the subgroup analyses of
older patients in the DURABLE trial initiation phase sup-
ported these guidelines. When the subgroup analyses of
older patients in the initiation phase and the current find-
ings in the maintenance phase are considered together, the
overall results might suggest that once glycemic control is
attained, perhaps a less aggressive approach may not be
necessary.
A potential limitation in this study is the imbalance in
the number of patients taking different OAM regimens; a
greater number of patients in the GL group versus the
LM75/25 group were taking the SU/TZD combination at
baseline. In addition, the high use of SU in this study may
have influenced the overall rates of hypoglycemia and
glycemic endpoints in both groups. Similar to the previous
analysis of older patients in the DURABLE trial initiation
phase [8], there was not an adequate comparative sample of
patients not taking SU to complete a valid analysis of
hypoglycemia rates and glycemic endpoints, but the pos-
sible contribution of concomitant SU use cannot be
excluded.
Another limitation of this study is the smaller number of
patients in the HbA1C B6.5 % subgroup (LM75/25,
n = 72; GL, n = 39), which limited the ability to draw
solid conclusions from the comparison of the two treatment
groups. Finally, detailed information on the use of non-
diabetes-related medications, comorbidities or dietary
habits was not collected in this trial. It is, therefore, diffi-
cult to determine the influence of other factors, such as
underlying illness, eating habits, alcohol use or concomi-
tant medications, on glucose control. Differences in dietary
habits across the various countries could have influenced
plasma glucose profiles.
Conclusions
Despite the limitations to this study, the findings suggest
that in older patients, the LM75/25 regimen resulted in
longer durability of glycemic control, a greater number of
patients maintaining HbA1C goal, and no increase in
hypoglycemia versus the GL regimen. However, this
improvement in glycemic control was associated with more
weight gain and modestly higher daily insulin doses. Fur-
ther evaluations of meal-time insulin in older patients are
warranted.
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